Mont-Saint-Guibert (Belgium), October 9, 2024, 10:35 pm CET / 4:35 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.
Contact:
Nyxoah
Loic Moreau, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$4.57 |
| Daily Change: | 0.03 0.66 |
| Daily Volume: | 111,107 |
| Market Cap: | US$196.650M |
November 13, 2025 November 13, 2025 September 23, 2025 September 02, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load